These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 21477587)

  • 1. Transcriptional and epigenetic networks in haematological malignancy.
    Cheung N; So CW
    FEBS Lett; 2011 Jul; 585(13):2100-11. PubMed ID: 21477587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic connections between autoimmune disorders and haematological malignancies.
    Javierre BM; Esteller M; Ballestar E
    Trends Immunol; 2008 Dec; 29(12):616-23. PubMed ID: 18951845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic inactivation of the miR-124-1 in haematological malignancies.
    Wong KY; So CC; Loong F; Chung LP; Lam WW; Liang R; Li GK; Jin DY; Chim CS
    PLoS One; 2011 Apr; 6(4):e19027. PubMed ID: 21544199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptional regulation by DNA methylation.
    Poetsch AR; Plass C
    Cancer Treat Rev; 2011; 37 Suppl 1():S8-12. PubMed ID: 21601364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EHA scientific workshop report: the role of epigenetics in hematological malignancies.
    Jost E; Galm O
    Epigenetics; 2007; 2(2):71-9. PubMed ID: 17965605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies.
    Amodio N; Rossi M; Raimondi L; Pitari MR; Botta C; Tagliaferri P; Tassone P
    Oncotarget; 2015 May; 6(15):12837-61. PubMed ID: 25968566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic alterations in hematopoietic malignancies.
    Chung YR; Schatoff E; Abdel-Wahab O
    Int J Hematol; 2012 Oct; 96(4):413-27. PubMed ID: 23015417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic modulation in hematologic malignancies: challenges and progress.
    Mitsiades CS; Anderson KC
    J Natl Compr Canc Netw; 2009 Nov; 7 Suppl 8():S1-12; quiz S14-6. PubMed ID: 19930971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspectives and future directions for epigenetics in hematology.
    Goodell MA; Godley LA
    Blood; 2013 Jun; 121(26):5131-7. PubMed ID: 23692857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic therapy in hematological cancers.
    Dimopoulos K; Grønbaek K
    APMIS; 2019 May; 127(5):316-328. PubMed ID: 30859683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular basis of hematological malignancies].
    Kitamura T; Inoue D; Nakahara F; Okochi N; Kato N; Togami K; Uchida T; Kagiyama Y; Kawabata KC; Nagase R; Horikawa S; Hayashi K; Saika M; Izawa K; Oki T; Chiba S; Harada Y; Harada H; Kitaura J
    Rinsho Ketsueki; 2014 Oct; 55(10):1715-23. PubMed ID: 25297732
    [No Abstract]   [Full Text] [Related]  

  • 12. DNA methyltransferases in hematological malignancies.
    Hoang NM; Rui L
    J Genet Genomics; 2020 Jul; 47(7):361-372. PubMed ID: 32994141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukaemogenesis: more than mutant genes.
    Chen J; Odenike O; Rowley JD
    Nat Rev Cancer; 2010 Jan; 10(1):23-36. PubMed ID: 20029422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies.
    Fratta E; Montico B; Rizzo A; Colizzi F; Sigalotti L; Dolcetti R
    Oncotarget; 2016 Aug; 7(35):57327-57350. PubMed ID: 27329599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNMT3A in haematological malignancies.
    Yang L; Rau R; Goodell MA
    Nat Rev Cancer; 2015 Mar; 15(3):152-65. PubMed ID: 25693834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chromosomal translocations in human malignant hematopoiesis. Structural and functional consequences].
    Nguyen Khac F; Bernard OA
    Pathol Biol (Paris); 2003 Aug; 51(6):382-9. PubMed ID: 12927896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigational epigenetically targeted drugs in early phase trials for the treatment of haematological malignancies.
    Okosun J; Packham G; Fitzgibbon J
    Expert Opin Investig Drugs; 2014 Oct; 23(10):1321-32. PubMed ID: 24855903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rebelled epigenome: histone H3S10 phosphorylation and H3S10 kinases in cancer biology and therapy.
    Komar D; Juszczynski P
    Clin Epigenetics; 2020 Oct; 12(1):147. PubMed ID: 33054831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetics in the hematologic malignancies.
    Fong CY; Morison J; Dawson MA
    Haematologica; 2014 Dec; 99(12):1772-83. PubMed ID: 25472952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic mechanisms regulating normal and malignant haematopoiesis: new therapeutic targets for clinical medicine.
    Bonifer C; Bowen DT
    Expert Rev Mol Med; 2010 Feb; 12():e6. PubMed ID: 20152067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.